Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer

Core Insights - Oncolytics Biotech Inc. is making significant progress in 2025 with advancements in regulatory and clinical areas, particularly for its immunotherapy pelareorep in hard-to-treat cancers [1][2][4] - Recent clinical data presentations at the ASCO Gastrointestinal Cancers Symposium have highlighted pelareorep's strong safety and efficacy signals in pancreatic and anal cancers [1][4][5] Regulatory Developments - The German Regulatory Agency has approved the continuation of the pancreatic cancer study, allowing full enrollment after a positive safety review [3][5] - Oncolytics has received positive feedback from regulators, facilitating the advancement of its pancreatic cancer study toward full enrollment [2][5] Clinical Data and Efficacy - At ASCO GI 2025, new clinical results were presented, confirming pelareorep's potential in pancreatic and anal cancers, which may lead to larger registration-enabling clinical trials [4][5] - Pelareorep has shown a favorable safety profile and strong efficacy signals when combined with modified FOLFIRINOX and atezolizumab in pancreatic cancer [5][8] Future Outlook - Oncolytics is entering a pivotal year with multiple upcoming milestones, including additional data readouts and interactions with regulatory agencies that could accelerate future trials [5][6] - The company is focused on advancing its clinical program in gastrointestinal cancers and moving toward registration-enabling studies in breast cancer [7][10]